KRAS and lung carcinoma: To further support the idea of miR-708 as a precision medicine for NRAS mutation-driven cancers, we overexpressed miR-708 in breast cancer cells and lung cancer cells carrying KRAS mutation, MDA-MB-231 and A549, as well as normal lung epithelial cells, BEAS-2B.